See other companies on Welcome to the Jungle
Pear Bio
Biomedical technologies for cancer treatment
- 1-20 employees
- Healthcare
- B2B
- Biology
- Computer Vision
- Canterbury, UK
Jump to section
Company mission
To help doctors and pharma companies evaluate cancer drug efficacy using organ-on-a-chip and computer vision.
Our take
Current anti-cancer drugs, such as chemotherapy, rely on targeting the DNA inside the cancer cell or cell surface proteins. However, often, these treatments targeting the cancer cell directly aren’t successful, because they are prevented from reaching the actual cells. Pear Bio has revolutionised cancer treatments by focusing on what’s on the outside of cancer cells. Its device models the outside of cancer cells, also known as the tumour microenvironment, which is an overlooked part of precision cancer medicine.
Another crucial problem Pear Bio is tackling is that fact that cancer is both a dynamic and unique disease that is constantly evolving, developing drug resistance and spreading. Pear Bio are personalising cancer treatment selection by developing a medical device that cultures patient tumour samples, monitors cancer cell behaviour during drug exposure, and eliminates all the ineffective treatments for that patient.
Pear Bio have created an "organ on chip" which recreates how cancel cells behave in their native environment. The company use the collected data to compute the cancer spread using 3D imaging and analyse the potential resistance to drugs. This helps oncologists to find the medication that is most likely to work on the patient quicker, helping save more lives.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Stock options
- Competitive compensation in line with industry standards
Funding (last 2 of 5 rounds)
Dec 2023
$0.3m
GRANT
May 2023
$14m
SERIES A
Total funding: $20.3m
This company has top investors
Leadership
Duleek Ranatunga
(Co-Founder & CEO)Experience in health-tech, med tech, materials science, oncology and 3D printing in academic research and start-up enviroments. Previously founded a company in oncology drug development.
William Lin
(Co-Founder)Previously been a Research Assistant at Harvard Medical School and Research Student at the University of Waterloo. Since then, worked at Avro Life Science as Technical Writer & Project Manager. Presently, is a freelance copywriter working at biotech/medtech companies.